Immunai
Decoding immunity
- Biotech
- United States
A drug discovery and development platform that maps the immune system to help biopharmaceutical companies identify novel targets, evaluate drug candidates, and
Summary
Immunai is an AI-driven drug discovery and development platform that provides integrated, end-to-end support for biopharmaceutical companies. The platform uses a high-resolution map of the immune system combined with AI-driven insights to support informed decision-making throughout the drug discovery and development process.
The company's integrated platform includes AMICA-Lab for single-cell profiling, AMICA-DB as the world's largest harmonized immune cell atlas, AMICA-One as an immune foundation model trained to predict drug response and resistance, and AMICA-Reason as an agentic reasoning engine that turns model outputs into mechanistic, actionable narratives.
Immunai serves three key solutions: Target Discovery to identify novel high-impact targets linked to disease, Preclinical Evaluation to prioritize the most promising drug candidates, and Clinical Trial Optimization to better understand drug mechanism of action and identify the right patient groups and treatment strategies. The company partners with leading biopharmaceutical companies including AstraZeneca and Teva.
Recorded features
- Single-cell profiling at the highest resolution (AMICA-Lab)
- World's largest harmonized immune cell atlas (AMICA-DB)
- Immune foundation model for drug response prediction (AMICA-One)
- Agentic reasoning engine for mechanistic insights (AMICA-Reason)
- Target discovery with robust experimental evidence
- Patient stratification capabilities
- Drug mechanism of action analysis
- Data-driven indication and dose selection
Compare and explore
Questions and answers
- What does Immunai's platform help biopharmaceutical companies accomplish?
- The platform supports decision-making throughout the drug discovery and development journey, helping companies make smarter choices, reduce risks, and accelerate progress with three key solutions: Target Discovery to identify novel high-impact targets, Preclinical Evaluation to prioritize promising candidates, and Clinical Trial Optimization to better understand drug mechanisms and maximize trial success.
- What are the main components of Immunai's integrated platform?
- The platform consists of four integrated components: AMICA-Lab for single-cell profiling, AMICA-DB which is the world's largest harmonized immune cell atlas, AMICA-One which is an immune foundation model trained to predict drug response and resistance, and AMICA-Reason which is an agentic reasoning engine that converts model outputs into mechanistic, actionable narratives.
- Which major biopharmaceutical companies does Immunai partner with?
- Immunai partners with top biopharmaceutical companies and research institutions, with notable collaborations including AstraZeneca for IBD target discovery and Teva for vitiligo research.
Leave a review for Immunai
No reviews of Immunai on the record yet. Start it.
Reviews go on record free. None are purchased. Open the record
Reviews on file · Record changes · Share the record · Your startup? Claim the record · Report an incorrect record
Immunai has a free listing. The owner can unlock the full profile with a paid launch for $5:
- Founder story (locked)
- Milestones (locked)
- Demo video (locked)
- Dofollow website link (locked)